Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$13.96
+1.0%
$11.38
$8.02
$18.55
$6.94B1.675.18 million shs1.26 million shs
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$35.73
-3.0%
$31.96
$27.34
$60.87
$6.58B0.131.33 million shs803,146 shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$40.97
+0.2%
$45.56
$20.08
$57.28
$1.72B0.83698,478 shs129,994 shs
Verona Pharma plc stock logo
VRNA
Verona Pharma
$92.21
+0.0%
$71.08
$14.14
$94.77
$7.49B0.211.32 million shs418,490 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%-0.90%+6.84%+29.83%-23.35%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.00%+5.23%+32.58%-2.93%-13.24%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.00%-6.90%-6.43%-13.90%+31.99%
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.00%+9.32%+29.29%+38.52%+508.98%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.0265 of 5 stars
1.22.00.00.31.31.70.0
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.2373 of 5 stars
3.51.00.00.03.31.70.6
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
1.9201 of 5 stars
3.50.00.00.02.22.50.6
Verona Pharma plc stock logo
VRNA
Verona Pharma
2.1078 of 5 stars
2.63.00.00.02.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.178.68% Upside
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.91
Moderate Buy$76.20113.27% Upside
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
3.00
Buy$66.6762.74% Upside
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.10
Buy$87.44-5.17% Downside

Current Analyst Ratings Breakdown

Latest TARS, ELAN, VRNA, and LEGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $110.00
6/2/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
6/2/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $90.00
5/27/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$72.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/14/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$88.00 ➝ $71.00
5/14/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/5/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.00
5/2/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$78.00 ➝ $84.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.57$2.88 per share4.84$12.63 per share1.10
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$728.30M9.02N/AN/A$6.88 per share5.19
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$233.67M7.37N/AN/A$5.95 per share6.88
Verona Pharma plc stock logo
VRNA
Verona Pharma
$118.54M63.07N/AN/A$3.10 per share29.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7434.9115.682.504.60%6.78%3.03%8/6/2025 (Estimated)
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$518.25M-$0.59N/AN/AN/A-66.92%-29.69%-19.45%8/8/2025 (Estimated)
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%8/6/2025 (Estimated)
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$54.37M-$2.00N/A3,073.67N/AN/A-79.54%-43.49%8/14/2025 (Estimated)

Latest TARS, ELAN, VRNA, and LEGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/1/2025Q1 2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million
4/29/2025Q1 2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.27
4.98
4.90
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.30
5.42
5.38
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.93
13.03
12.88

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
70.89%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%
Verona Pharma plc stock logo
VRNA
Verona Pharma
85.88%

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.02%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
8.97%
Verona Pharma plc stock logo
VRNA
Verona Pharma
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Legend Biotech Co. stock logo
LEGN
Legend Biotech
1,070183.76 million182.60 millionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5042.01 million35.07 millionOptionable
Verona Pharma plc stock logo
VRNA
Verona Pharma
3081.08 million76.10 millionOptionable

Recent News About These Companies

Verona Pharma plc (NASDAQ:VRNA) CFO Sells $4,560,000.00 in Stock
Cantor Fitzgerald Predicts Verona Pharma FY2025 Earnings
Cantor Fitzgerald Comments on Verona Pharma FY2026 Earnings
Verona Pharma (NASDAQ:VRNA) Trading Up 4.5% on Analyst Upgrade

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$13.96 +0.15 (+1.05%)
As of 12:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$35.73 -1.10 (-2.99%)
As of 12:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$40.96 +0.08 (+0.18%)
As of 12:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Verona Pharma stock logo

Verona Pharma NASDAQ:VRNA

$92.21 +0.01 (+0.01%)
As of 12:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.